paclitaxel/oksentaminen

Linkki tallennetaan leikepöydälle

Artikkelit Kliiniset tutkimuksetPatentit

Valitse lajittelutyyppi

Sivu 1 alkaen 596 tuloksia

Short-course olanzapine to prevent delayed emesis following carboplatin/paclitaxel for gynecologic cancer: a randomised study.

Vain rekisteröityneet käyttäjät voivat kääntää artikkeleita

Kirjaudu sisään Rekisteröidy

To explore efficacy of short-course olanzapine with or without low-dose dexamethasone for prevention of delayed emesis in gynecologic cancer patients receiving carboplatin/paclitaxel.This was a prospective study in 81 chemo-naive patients receiving 0.25 mg

Effects of ginger adjunct to the standard prophylaxis on reducing carboplatin and paclitaxel-induced nausea vomiting: a randomized controlled study.

Vain rekisteröityneet käyttäjät voivat kääntää artikkeleita

Kirjaudu sisään Rekisteröidy

To determine effects of ginger on reducing the severity of nausea and/or vomiting among gynecologic cancer patients receiving a combined carboplatin-paclitaxel regimen.The research was a randomized, double-blinded, crossover, placebo-controlled trial.

Is a dexamethasone-sparing strategy capable of preventing acute and delayed emesis caused by combined doxorubicin and paclitaxel for breast cancer? Analysis of a phase II trial.

Vain rekisteröityneet käyttäjät voivat kääntää artikkeleita

Kirjaudu sisään Rekisteröidy

OBJECTIVE The effectiveness of palonosetron without delayed dexamethasone dosing against emesis was investigated in patients scheduled to receive the corticosteroid-containing combination of doxorubicin and paclitaxel (AT) for 3 cycles. METHODS Chemo-naïve women with breast cancer receiving

A phase II clinical trial of palonosetron for the management of delayed vomiting in gynecological cancer patients receiving paclitaxel/carboplatin therapy.

Vain rekisteröityneet käyttäjät voivat kääntää artikkeleita

Kirjaudu sisään Rekisteröidy

There are currently no studies demonstrating the effects of palonosetron on delayed chemotherapy-induced nausea and vomiting (CINV) in gynecological cancer patients receiving chemotherapy with moderately emetogenic chemotherapeutic agents. We conducted a phase II clinical trial to assess the

Palonosetron in combination with 1-day versus 3-day dexamethasone to prevent nausea and vomiting in patients receiving paclitaxel and carboplatin.

Vain rekisteröityneet käyttäjät voivat kääntää artikkeleita

Kirjaudu sisään Rekisteröidy

OBJECTIVE The aim of the present study was to evaluate the efficacy and toxicity of palonosetron (PAL) and dexamethasone (DEX) on day 1 only in patients with gynecologic cancer receiving paclitaxel combined with carboplatin (TC). The primary endpoint was to evaluate the complete response (CR) rate

Safety and efficacy of aprepitant, ramosetron, and dexamethasone for chemotherapy-induced nausea and vomiting in patients with ovarian cancer treated with paclitaxel/carboplatin.

Vain rekisteröityneet käyttäjät voivat kääntää artikkeleita

Kirjaudu sisään Rekisteröidy

OBJECTIVE Women with ovarian carcinoma that are treated with paclitaxel/carboplatin are particularly susceptible to chemotherapy-induced nausea and vomiting (CINV). The current study evaluated the new combination (aprepitant/ramosetron/dexamethasone, 20 mg) in ovarian cancer patients receiving

Palonosetron in combination with 1-day versus 3-day dexamethasone for prevention of nausea and vomiting following paclitaxel and carboplatin in patients with gynecologic cancers: A randomized, multicenter, phase-II trial.

Vain rekisteröityneet käyttäjät voivat kääntää artikkeleita

Kirjaudu sisään Rekisteröidy

OBJECTIVE Chemotherapy-induced nausea and vomiting (CINV) can affect a patient's quality of life, leading to poor compliance with further treatments. Previous studies have provided minimal data about carboplatin-based regimens. Female sex is a known risk factor for CINV. The purpose of this study

Efficacy of aprepitant for the prevention of chemotherapy-induced nausea and vomiting with a moderately emetogenic chemotherapy regimen: a multicenter, placebo-controlled, double-blind, randomized study in patients with gynecologic cancer receiving paclitaxel and carboplatin.

Vain rekisteröityneet käyttäjät voivat kääntää artikkeleita

Kirjaudu sisään Rekisteröidy

BACKGROUND Substance P contributes to the hypersensitivity reaction (HSR) to paclitaxel in a rat model. Aprepitant acts as an inhibitor of the binding of substance P to the neurokinin-1 receptor and, consequently, may reduce the frequency of paclitaxel-induced HSR. While aprepitant has a

Evaluation of the relation between patient characteristics and the state of chemotherapy-induced nausea and vomiting in patients with gynecologic cancer receiving paclitaxel and carboplatin.

Vain rekisteröityneet käyttäjät voivat kääntää artikkeleita

Kirjaudu sisään Rekisteröidy

OBJECTIVE An antiemetic regimen for patients taking paclitaxel and carboplatin (TC) includes dexamethasone (20 mg) to protect against hypersensitivity. Chemotherapy-induced nausea and vomiting (CINV), however, is difficult to adequately control in patients receiving TC. In the present study, we

Additive effect of rikkunshito, an herbal medicine, on chemotherapy-induced nausea, vomiting, and anorexia in uterine cervical or corpus cancer patients treated with cisplatin and paclitaxel: results of a randomized phase II study (JORTC KMP-02).

Vain rekisteröityneet käyttäjät voivat kääntää artikkeleita

Kirjaudu sisään Rekisteröidy

OBJECTIVE Rikkunshito, an herbal medicine, is widely prescribed in Japan for the treatment of anorexia and functional dyspepsia, and has been reported to recover reductions in food intake caused by cisplatin. We investigated whether rikkunshito could improve chemotherapy-induced nausea and vomiting

Clinical Efficacy of Aprepitant in Patients with Gynecological Cancer after Chemotherapy Using Paclitaxel and Carboplatin.

Vain rekisteröityneet käyttäjät voivat kääntää artikkeleita

Kirjaudu sisään Rekisteröidy

OBJECTIVE This study aimed to evaluate the efficacy of aprepitant, a neurokinin (NK)1 receptor antagonist, on chemotherapy-induced nausea and vomiting (CINV). METHODS A randomized, open-labeled, parallel-design study was undertaken in gynecologic-cancer (GC) patients at the Fukuoka University

Pharmacokinetics of paclitaxel and carboplatin in a dose-escalating and dose-sequencing study in patients with non-small-cell lung cancer. The European Cancer Centre.

Vain rekisteröityneet käyttäjät voivat kääntää artikkeleita

Kirjaudu sisään Rekisteröidy

OBJECTIVE To investigate the pharmacokinetics and pharmacodynamics of paclitaxel (P) and carboplatin (C) in a sequence-finding and dose-escalating study in untreated non-small-cell lung cancer (NSCLC) patients. METHODS Fifty-five chemotherapy-naive patients with NSCLC were entered onto the

Triplet combination with paclitaxel, cisplatin and 5-FU is effective in metastatic and/or recurrent nasopharyngeal carcinoma.

Vain rekisteröityneet käyttäjät voivat kääntää artikkeleita

Kirjaudu sisään Rekisteröidy

OBJECTIVE Platinum-based chemotherapy is the recognized first-line treatment for metastatic nasopharyngeal carcinoma (NPC). However, no standard treatment regimens have been established. This phase II study was designed to evaluate the efficacy and safety of a paclitaxel, cisplatin and 5-FU

A Randomized Controlled Pilot Study Comparing the Impact of Aprepitant and Fosaprepitant on Chemotherapy Induced Nausea and Vomiting in Patients Treated for Gynecologic Cancer.

Vain rekisteröityneet käyttäjät voivat kääntää artikkeleita

Kirjaudu sisään Rekisteröidy

OBJECTIVE The purpose of this pilot study was to compare the response rates and daily living activities of patients with newly diagnosed gynecologic cancer treated with fosaprepitant or aprepitant in the management of chemotherapy-induced nausea and vomiting. METHODS Eligible participants were

Toxicity and outcome analysis of patients with recurrent head and neck cancer treated with hyperfractionated split-course reirradiation and concurrent cisplatin and paclitaxel chemotherapy from two prospective phase I and II studies.

Vain rekisteröityneet käyttäjät voivat kääntää artikkeleita

Kirjaudu sisään Rekisteröidy

BACKGROUND Patients with local recurrences or new head and neck primary tumors in previously irradiated tissues have few options for salvage treatment. One option for select patients is to undergo reirradiation with concurrent chemotherapy. The purpose of this study is to report the initial clinical

Edellinen
1
2
3
4
5
6
...
39
40
Seuraava

Liity facebook-sivullemme

Herbal & Natural Medicine

Täydellisin lääketieteellinen tietokanta tieteen tukemana

Toimii 55 kielellä
Yrttilääkkeet tieteen tukemana
Yrttien tunnistaminen kuvan perusteella
Interaktiivinen GPS-kartta - merkitse yrtit sijaintiin (tulossa pian)
Lue hakuusi liittyviä tieteellisiä julkaisuja
Hae lääkekasveja niiden vaikutusten perusteella
Järjestä kiinnostuksesi ja pysy ajan tasalla uutisista, kliinisistä tutkimuksista ja patenteista

Kirjoita oire tai sairaus ja lue yrtteistä, jotka saattavat auttaa, kirjoita yrtti ja näe taudit ja oireet, joita vastaan sitä käytetään.
* Kaikki tiedot perustuvat julkaistuun tieteelliseen tutkimukseen